Moreover, higher expression of tumor CD44 has been associated with poor prognosis in patients with various cancers, such as non-small cell lung cancer [15], gastric cancer [16], hepatocellular carcinoma [17], colorectal cancer [18], renal cell carcinoma [19], breast cancer [20], ovarian cancer [21], head and neck cancer [22], and osteosarcoma [23]. This evidence concerns the gene CD44 and neoplasm.